GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and ...
PridCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, designed to hinder the SARS-CoV-2 virus’s ability to replicate. Clinical ...
Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...
Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed. When you purchase through links on our ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback